Vimarsana
Biggest News Aggregation in the World

Page 19 - Small Molecules News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Small Molecules. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Small Molecules Today - Breaking & Trending Today

Adhoc: Lonza Group AG: Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory - Vimarsana News

Adhoc: Lonza Group AG: Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory

Lonza Group AG / Key word(s): Quarter Results Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory 10-May-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant

 - Vimarsana News

Lonza Group AG / Key word: Quarter Results Q1 2023 Qualitative Update: Business Performance In Line With  Full-Year Trajectory 10-May-2023 / 07:00 CET/CEST Release of an ad hoc announcement... | May 10, 2023

Anticoronavirals: the development of COVID-19 therapies and the challenges that remain - Vimarsana News

Anticoronavirals: the development of COVID-19 therapies and the challenges that remain

Researchers highlighted the pace of development of COVID-19 therapies during the pandemic and the challenges that hinder the widespread availability of anticoronavirals.

Lonza Group AG (OTCMKTS:LZAGY) Plans Dividend Increase – $0.11 Per Share - Vimarsana News

Lonza Group AG (OTCMKTS:LZAGY) Plans Dividend Increase – $0.11 Per Share

Lonza Group AG (OTCMKTS:LZAGY – Get Rating) declared a dividend on Thursday, May 4th, investing.com reports. Investors of record on Wednesday, May 10th will be paid a dividend of 0.108 per share on Friday, May 26th. This represents a yield of 0.17%. The ex-dividend date of this dividend is Tuesday, May 9th. This is a […]

Crohn's disease: Symptoms, diagnosis, and treatments - Vimarsana News

Crohn's disease: Symptoms, diagnosis, and treatments

Anyone newly diagnosed with Crohn's disease likely has a lot of questions – and probably some anxiety – about having a chronic ailment for which there's no cure.